The company manufactures and sells plastic injection-moulded components for consumer appliances and automotive sectors, while also producing composite parts for railways and trading hair accessories under the Divo brand.
The company lacks a durable moat, as evidenced by razor-thin net margins of 1.5% and low ROE of 5.4%, indicating it operates as a price-taking subcontractor for large OEMs. While it has long-standing relationships with white goods brands, the lack of pricing power is clear from the inability to pass on raw material cost increases, leading to profit declines despite revenue growth.
Capital has been deployed toward domestic capacity expansion and a small US acquisition to enter the North American railway market. However, these investments have yet to translate into meaningful bottom-line growth or high returns on capital, with ROCE hovering around 12%.
Five years out, the company collapsed under the weight of its own inefficiency. While revenue grew, the razor-thin 1.5% net margins were entirely consumed by rising raw material costs and interest on debt used for the US expansion. The family-led management failed to integrate the North American acquisition, and the lack of pricing power meant they were effectively subsidizing their OEM customers' profits until the equity was hollowed out by persistent low returns on capital.
RichFakir rates Bright Brothers Ltd's business quality as poor — 21/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Bright Brothers Ltd is trading about 49% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Bright Brothers Ltd is: Not rated. A poor business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Bright Brothers Ltd's fair value is about ₹157 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →